Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Yarmus is a Professor of Medicine and Oncology and the director of Interventional Pulmonology at the Johns Hopkins University School of Medicine as well as the Vice Chair of Medicine for Strategy and Finance. He is an expert in the minimally invasive diagnosis and treatment of lung cancer and he leads the Interventional Pulmonary research program at Johns Hopkins with research investigating innovative minimally invasive device development and early-stage bronchoscopic treatments. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management, pleural diseases and symptom relief with minimally invasive procedures such as indwelling pleural catheters and pleurodesis. Dr. Yarmus is a member of the Fleischner Society and a fellow of the American College of Chest Physicians and the American Thoracic Society. Dr. Yarmus is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Dr. Lee is a specialist in Interventional Pulmonary and serves as the Wang Interventional Pulmonary Fellowship Director. His areas of clinical expertise include interventional pulmonology, pleural disease, minimal invasive diagnostics and lung cancer at Johns Hopkins. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management and difficulty airways. In addition, he specializes in the diagnosis and management of pleural diseases and symptom relief with minimally invasive procedures. He is a fellow of the American College of Chest Physicians and the Johns Hopkins Master of Education for Health Professionals. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Cornelious Musara is a General Surgeon in Glen Burnie, Maryland. Dr. Musara is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Gallstones, Gallbladder Disease, Choledocholithiasis, Hernia Surgery, and Ureteroscopy.

Peter Olivieri is an Intensive Care Medicine provider in Glen Burnie, Maryland. Dr. Olivieri is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Nodules, Lung Cancer, Squamous Cell Lung Carcinoma, Gastrostomy, and Advanced Bronchoscopy.

Yudhishtra Markan is a Hematologist Oncology specialist and an Oncologist in Glen Burnie, Maryland. Dr. Markan is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer.

Elizabeth Mcilmoyle is an Intensive Care Medicine provider in Glen Burnie, Maryland. Dr. Mcilmoyle is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Pleurisy, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Obstructive Sleep Apnea.

Darwin Ashbaker is an Intensive Care Medicine provider in Glen Burnie, Maryland. Dr. Ashbaker is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Nodules, Lung Cancer, Pneumonia, Gastrostomy, and Endoscopy.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Jeffrey Thiboutot is a primary care provider, practicing in Pulmonary Medicine in Baltimore, Maryland. Dr. Thiboutot is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Nodules, Pleurisy, Lymphofollicular Hyperplasia, Lung Cancer, and Endoscopy.

Christine Argento is a Pulmonary Medicine provider in Baltimore, Maryland. Dr. Argento is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Pleural Effusion, Lymphofollicular Hyperplasia, Lung Nodules, Endoscopy, and Gastrostomy.

Dr. Mullen attended the University of Virginia, graduating in 1987 with a BA in Chemistry and Spanish. She then attended medical school at Columbia University College of Physicians and Surgeons, graduating in 1991. After an internship in Internal Medicine at the Hospital of the University of Pennsylvania, she returned to Columbia Presbyterian Medical Center (now New York Presbyterian Hospital) for her residency in Diagnostic Radiology. She served at Co-Chief Resident from 1995 to 1996. Dr. Mullen completed her fellowship in Cross-Sectional Imaging (Ultrasound, CT and MRI) at Johns Hopkins Hospital in 1997. Dr. Mullen worked in private practice for 5 years, gaining experience in general radiology, and developing interest and expertise in breast imaging, women's imaging, and body imaging. She joined Johns Hopkins Radiology in 2002, and has been based at Johns Hopkins Imaging at Green Spring. Dr. Mullen has expertise in screening and diagnostic mammography, breast ultrasound, breast MRI, and breast interventional procedures, as well as general ultrasound and bone densitometry. Dr. Mullen is interested in clinical breast imaging and resident and fellow education. She has been the Breast Imaging Fellowship Director since 2013. Dr. Mullen is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Fibrocystic Breast Disease, Lymphofollicular Hyperplasia, Osteopenia, and Melorheostosis with Osteopoikilosis.

Zuzana Chamrova is a Radiologist and an Interventional Radiologist in Glen Burnie, Maryland. Dr. Chamrova is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Ascites, Endometrial Cancer, Pleurisy, Bone Marrow Aspiration, and Vertebroplasty.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

I am medical oncologist dedicated to the care of patients with genitourinary malignancies. My clinical and research focus is on the management of renal cell carcinoma (RCC). I have completed Medical Oncology Higher Specialist Training with Royal College of Physicians in Ireland and subsequently completed Advanced Medical Oncology Fellowship at the Memorial Sloan Kettering Cancer Center in New York. Dr. Ged is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Dr. Lechtzin is a pulmonary and critical care medicine physician. He directs the Adult CF program and the neuromuscular pulmonary clinic at Johns Hopkins and is an expert in the treatment of cystic fibrosis, pulmonary complications of neuromuscular disease and the care of critically ill patients in the Medical ICU. He is a member of the Longcope Firm Faculty and provides teaching to medical students and residents at Johns Hopkins. Dr. Lechtzin is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, Lung Transplant, and Endoscopy.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Lum is a clinically busy vascular surgeon specializing in the open and endovascular treatment of peripheral arterial disease, cartoid artery disease, dialysis access, mesenteric occlusive disease, arterial aneurysms and venous disease. In addition, he has a strong clinical & research interest in thoracic outlet syndrome. Dr Lum also has a Masters in Public Health from the Johns Hopkins School of Public Health. Dr. Lum is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Thoracic Outlet Syndrome, Thoracic Aortic Aneurysm, Abdominal Aortic Aneurysm (AAA), Carotid Artery Surgery, and Osteotomy.

Daniel Rhee, M.D., M.P.H., joins the Johns Hopkins Department of Surgery as Assistant Professor of Surgery and Director of the Pediatric Surgical Oncology Program. Dr. Rhee’s areas of clinical expertise include pediatric surgical oncology as well as neonatal and general pediatric surgery. Dr. Rhee received his undergraduate degree from the University of Michigan and earned his medical degree from The Ohio State University College of Medicine. He completed his residency in general surgery at St. Joseph Mercy Hospital before completing fellowships at Johns Hopkins Hospital in Pediatric Surgery and Memorial Sloan Kettering Cancer Center in Pediatric Surgical Oncology. Dr. Rhee is a member of several professional societies, including the American College of Surgeons, American Pediatric Surgical Association, the Association of Academic Surgeons, the Children’s Oncology Group, and The International Society of Paediatric Surgical Oncology. Dr. Rhee’s research interests involve childhood tumors including neuroblastoma, sarcoma, Wilms tumor, hepatoblastoma, pancreatoblastoma, reconstruction for chest wall tumors, germ cell tumors, and desmoplastic small round cell tumors. His research interests also include use of 3D printing for simulation for surgical training, improving surgical outcomes in pediatric surgery and improving access to surgical care in low and middle-income countries. Dr. Rhee is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Adult Soft Tissue Sarcoma, Appendicitis, Tracheoesophageal Fistula, Appendectomy, and Pancreaticoduodenectomy.